Global Clinical Trials Day
On the occasion of the International Clinical Trials Day took place in the work of the 2nd ATHENS HEALTH FORUM, under the auspices of SFEE special session on "Clinical research and innovative therapies in Greece: Necessity or luxury?". Clinical research is an issue of fundamental value for both patients and for Greece. We have a new epidemiological profile across Europe characterized by an aging population and the increase in chronic diseases, which requires the participation of many more people in clinical studies. Innovation with the human resources are the two main factors which have to support clinical research. That said, this day marks the recognition of the contribution of thousands of participants in clinical studies not only in our country but throughout Europe thanks to which progress has been made in many diseases, progress which in several cases translates to an increase life expectancy, a reduction of mortality rates in diseases such as HIV and cancer and to cure incurable until recently diseases such as Hepatitis C.
Opening of the Congress, the President of SFEE, Mr.. Paschalis Apostolidis, referring to the total of the Sector Strategy underlined the willingness of the Association to support operations, expertise, new proposals to the country's efforts to emerge from the adventure of recent years and help it become a competitive force in the field of drugs and especially in attracting Clinical Trials. Clinical studies are "oxygen" to the human capital and the country's economy as a time approved a clinical study "imported" to Greece about 250.000 € and is caused, according to the published financial multipliers, net increase in GDP of our country, which goes where the 500.000 € per clinical trial (study details an influenza pandemic). The pharmaceutical industry intends to invest further in Clinical Research fostering growth in the Greek economy and society, ypertetraplasiazontas research funds within 2-3 years. However, he stressed that the key issue is "to encourage and provide incentives for the investment plans of the Sector and resolving malfunctions not favored so far any corporate decisions on further investments in the country eg the production and clinical studies can actually translate directly into new resources and new jobs, so growth that our country needs this period and implementation of health policy which now redrawn ".
Opening of the Congress, the President of SFEE, Mr.. Paschalis Apostolidis, referring to the total of the Sector Strategy underlined the willingness of the Association to support operations, expertise, new proposals to the country's efforts to emerge from the adventure of recent years and help it become a competitive force in the field of drugs and especially in attracting Clinical Trials. Clinical studies are "oxygen" to the human capital and the country's economy as a time approved a clinical study "imported" to Greece about 250.000 € and is caused, according to the published financial multipliers, net increase in GDP of our country, which goes where the 500.000 € per clinical trial (study details an influenza pandemic). The pharmaceutical industry intends to invest further in Clinical Research fostering growth in the Greek economy and society, ypertetraplasiazontas research funds within 2-3 years. However, he stressed that the key issue is "to encourage and provide incentives for the investment plans of the Sector and resolving malfunctions not favored so far any corporate decisions on further investments in the country eg the production and clinical studies can actually translate directly into new resources and new jobs, so growth that our country needs this period and implementation of health policy which now redrawn ".